MOG-19

MOG-19 is a small molecule multi-kinase inhibitor belonging to the moguntinone class, which consists of 3-indolyl and 3-azaindolyl-4-aryl maleimide derivatives. Developed by researchers at the Johannes Gutenberg University Mainz, MOG-19 is designed to target protein kinases associated with tumor growth, metastasis, and angiogenesis. Preclinical studies in human colorectal cancer (CRC) models have demonstrated that MOG-19 potently inhibits glycogen synthase kinase 3 beta (GSK3β) and signaling pathways downstream of the mechanistic target of rapamycin (mTOR). The compound exhibits significant proapoptotic, antiangiogenic, and antiproliferative effects, particularly when used in synergistic combination with topoisomerase I inhibitors such as irinotecan. In vivo xenograft models have further validated its potential to reduce tumor volume and weight, suggesting its value as a complement to standard chemotherapy options for colorectal cancer.

Other names

moguntinone-19moguntinone19moguntinone 19